tradingkey.logo
๎™

Biontech SE

BNTX
99.850USD
+1.000+1.01%
์ข…๊ฐ€ย 01/09, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
24.01B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Biontech SE ํšŒ์‚ฌ

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Biontech SE ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ BNTX
ํšŒ์‚ฌ ์ด๋ฆ„Biontech SE
์ƒ์žฅ์ผOct 10, 2019
CEOSahin (Ugur)
์ง์› ์ˆ˜6772
์œ ํ˜•Depository Receipt
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒOct 10
์ฃผ์†ŒAn der Goldgrube 12
๋„์‹œMAINZ
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Germany
์šฐํŽธ ๋ฒˆํ˜ธ55131
์ „ํ™”4949613190840
์›น์‚ฌ์ดํŠธhttps://www.biontech.com/
์ข…๋ชฉ ์ฝ”๋“œ BNTX
์ƒ์žฅ์ผOct 10, 2019
CEOSahin (Ugur)

Biontech SE์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Mar 12
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Mar 12
FY2019
FY2018
FY2017
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Nov 15
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Nov 15
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
๊ธฐํƒ€
38.36%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
๊ธฐํƒ€
38.36%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Corporation
59.74%
Investment Advisor
15.63%
Investment Advisor/Hedge Fund
3.83%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
๊ธฐํƒ€
15.43%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
774
54.93M
21.75%
-6.01M
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
AT Impf GmbH
101.85M
40.33%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
15.89%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
7.88M
3.12%
-159.51K
-1.98%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.98M
1.97%
-2.00M
-28.65%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
4.83M
1.91%
+1.24M
+34.32%
Sep 30, 2025
Flossbach von Storch AG
4.23M
1.68%
-65.00
-0.00%
Sep 30, 2025
PRIMECAP Management Company
3.87M
1.53%
-130.70K
-3.27%
Sep 30, 2025
Dodge & Cox
3.65M
1.44%
+2.77M
+315.65%
Sep 30, 2025
Sahin (Ugur MD)
2.05M
0.81%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
1.66M
0.66%
-2.00M
-54.67%
Sep 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
๋” ๋ณด๊ธฐ
Langar Global HealthTech ETF
๋น„์œจ4.06%
iShares Genomics Immunology and Healthcare ETF
๋น„์œจ3.6%
First Trust NYSE Arca Biotechnology Index Fund
๋น„์œจ3.42%
Global X Genomics & Biotechnology ETF
๋น„์œจ3.11%
WisdomTree BioRevolution Fund
๋น„์œจ2.74%
Franklin Genomic Advancements ETF
๋น„์œจ2.46%
VanEck Biotech ETF
๋น„์œจ2.38%
Virtus LifeSci Biotech Products ETF
๋น„์œจ1.58%
ProShares Ultra Nasdaq Biotechnology
๋น„์œจ1.02%
Invesco Nasdaq Biotechnology ETF
๋น„์œจ1.01%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Biontech SE์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Biontech SE์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
AT Impf GmbH๋Š” 101.85M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 40.33%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Medine GmbH๋Š” 40.13M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 15.89%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Baillie Gifford & Co.๋Š” 7.88M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.12%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Fidelity Management & Research Company LLC๋Š” 4.98M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 1.97%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
T. Rowe Price Investment Management, Inc.๋Š” 4.83M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 1.91%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Biontech SE์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Biontech SE์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.์ž…๋‹ˆ๋‹ค.

Biontech SE(BNTX)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q4 ๊ธฐ์ค€์œผ๋กœ, Biontech SE์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 774๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 54.93M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 21.75%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q3 ๋Œ€๋น„ -3.93% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Biontech SE์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
FY2019 ๊ธฐ์ค€, Biontech SE์˜ Collaboration Revenue ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 84.43M๋กœ ์ „์ฒด ๋งค์ถœ์˜ 77.75%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™